PMID- 34107056
OWN - NLM
STAT- MEDLINE
DCOM- 20211228
LR  - 20211228
IS  - 1365-2249 (Electronic)
IS  - 0009-9104 (Print)
IS  - 0009-9104 (Linking)
VI  - 205
IP  - 3
DP  - 2021 Sep
TI  - Anti-vimentin/cardiolipin IgA in the anti-phospholipid syndrome: A new tool for 
      'seronegative' diagnosis.
PG  - 326-332
LID - 10.1111/cei.13633 [doi]
AB  - Anti-phospholipid syndrome (APS) is a systemic autoimmune disorder defined by the 
      simultaneous presence of vascular clinical events, pregnancy morbidity and 
      anti-phospholipid antibodies (aPL). In clinical practice, it is possible to find 
      patients with APS who are persistently negative for the routine aPL tests 
      (seronegative APS; SN-APS). Recently, the identification of aPL immunoglobulin 
      (Ig)A and/or anti-beta2-glycoprotein-I (beta2-GPI) IgA was shown to represent a further 
      test in SN-APS patients. In this study we analyzed the presence of 
      anti-vimentin/cardiolipin (aVim/CL) IgA in a large cohort of patients with 
      SN-APS, evaluating their possible association with clinical manifestations of the 
      syndrome. This study includes 60 consecutive SN-APS patients, 30 patients with 
      APS and 40 healthy donors. aVim/CL IgA were detected by enzyme-linked 
      immunosorbent assay (ELISA). Results show that 12 of 30 APS patients (40%) and 16 
      of 60 SN-APS patients (26.7%) resulted positive for aVim/CL IgA. Interestingly, 
      SN-APS patients who tested positive for aVim/CL IgA showed a higher prevalence of 
      arterial thrombosis (p = 0.017, likelihood positive ratio = 5.7). This study 
      demonstrates for the first time, to our knowledge, the presence of aVim/CL IgA in 
      sera of patients with APS. In particular, they revealed a potential usefulness in 
      identification of a significant proportion of SN-APS patients. Moreover, as 
      patients tested positive for aVim/CL IgA reported a high likelihood ratio to have 
      the clinical features of APS, this test may be considered a suitable approach in 
      the clinical evaluation of SN-APS.
CI  - (c) 2021 The Authors. Clinical & Experimental Immunology published by John Wiley & 
      Sons Ltd on behalf of British Society for Immunology.
FAU - Capozzi, Antonella
AU  - Capozzi A
AD  - Dipartimento di Medicina Sperimentale, Sapienza University, Rome, Italy.
FAU - Riitano, Gloria
AU  - Riitano G
AD  - Dipartimento di Medicina Sperimentale, Sapienza University, Rome, Italy.
FAU - Mancuso, Silvia
AU  - Mancuso S
AD  - Reumatologia, Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche 
      Cardiovascolari, Sapienza University, Rome, Italy.
FAU - Recalchi, Serena
AU  - Recalchi S
AD  - Dipartimento di Medicina Sperimentale, Sapienza University, Rome, Italy.
FAU - Manganelli, Valeria
AU  - Manganelli V
AD  - Dipartimento di Medicina Sperimentale, Sapienza University, Rome, Italy.
FAU - Garofalo, Tina
AU  - Garofalo T
AD  - Dipartimento di Medicina Sperimentale, Sapienza University, Rome, Italy.
FAU - Alessandri, Cristiano
AU  - Alessandri C
AD  - Reumatologia, Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche 
      Cardiovascolari, Sapienza University, Rome, Italy.
FAU - Longo, Agostina
AU  - Longo A
AD  - Dipartimento di Medicina Sperimentale, Sapienza University, Rome, Italy.
FAU - Misasi, Roberta
AU  - Misasi R
AD  - Dipartimento di Medicina Sperimentale, Sapienza University, Rome, Italy.
FAU - Conti, Fabrizio
AU  - Conti F
AD  - Reumatologia, Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche 
      Cardiovascolari, Sapienza University, Rome, Italy.
FAU - Truglia, Simona
AU  - Truglia S
AD  - Reumatologia, Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche 
      Cardiovascolari, Sapienza University, Rome, Italy.
FAU - Sorice, Maurizio
AU  - Sorice M
AUID- ORCID: 0000-0003-3534-1502
AD  - Dipartimento di Medicina Sperimentale, Sapienza University, Rome, Italy.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210629
PL  - England
TA  - Clin Exp Immunol
JT  - Clinical and experimental immunology
JID - 0057202
RN  - 0 (Antibodies, Anticardiolipin)
RN  - 0 (Antibodies, Antiphospholipid)
RN  - 0 (Immunoglobulin A)
RN  - 0 (VIM protein, human)
RN  - 0 (Vimentin)
RN  - 0 (beta 2-Glycoprotein I)
SB  - IM
MH  - Adult
MH  - Antibodies, Anticardiolipin/*blood
MH  - Antibodies, Antiphospholipid/*blood
MH  - Antiphospholipid Syndrome/blood/*diagnosis/immunology
MH  - Female
MH  - Humans
MH  - Immunoglobulin A/*blood/immunology
MH  - Lupus Erythematosus, Systemic/diagnosis
MH  - Male
MH  - Middle Aged
MH  - Thrombosis/epidemiology
MH  - Vimentin/*immunology
MH  - beta 2-Glycoprotein I/immunology
PMC - PMC8374216
OTO - NOTNLM
OT  - IgA isotype
OT  - aVim/CL antibodies
OT  - anti-phospholipid syndrome
OT  - seronegative APS
COIS- The authors state no conflicts of interest.
EDAT- 2021/06/10 06:00
MHDA- 2021/12/29 06:00
PMCR- 2021/06/29
CRDT- 2021/06/09 17:31
PHST- 2021/05/28 00:00 [revised]
PHST- 2021/05/07 00:00 [received]
PHST- 2021/05/28 00:00 [accepted]
PHST- 2021/06/10 06:00 [pubmed]
PHST- 2021/12/29 06:00 [medline]
PHST- 2021/06/09 17:31 [entrez]
PHST- 2021/06/29 00:00 [pmc-release]
AID - CEI13633 [pii]
AID - 10.1111/cei.13633 [doi]
PST - ppublish
SO  - Clin Exp Immunol. 2021 Sep;205(3):326-332. doi: 10.1111/cei.13633. Epub 2021 Jun 
      29.